SAB Biotherapeutics (SABS) Exchange Rate Effect (2024 - 2026)
SAB Biotherapeutics (SABS) reported Exchange Rate Effect of $14729.0 for Q1 2026, down 65.34% on a YoY basis from $42500.0 in Q1 2025, and up 103.7% quarter-over-quarter from -$397861.0 in Q4 2025.
SAB Biotherapeutics (SABS) Exchange Rate Effect (2024 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Exchange Rate Effect for 3 years, with the latest figure at $14729.0 in Q1 2026.
- For the quarter ending Q1 2026, Exchange Rate Effect fell 65.34% year-over-year to $14729.0; the trailing twelve-month figure through Mar 2026 stood at -$241268.0 (down 41.57% YoY), and the FY2025 full-year result was -$213497.0, up 11.48% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at $14729.0, up from -$397861.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $179401.0 in Q2 2025, with the low at -$397861.0 in Q4 2025.
- Historically, Exchange Rate Effect has averaged -$48885.1 across 3 years, with a median of $14729.0 in 2026.
- The largest YoY upside for Exchange Rate Effect was 534.31% in 2025 against a maximum downside of 178.96% in 2025.
- SAB Biotherapeutics' Exchange Rate Effect stood at -$288748.0 in 2024, then plunged by 37.79% to -$397861.0 in 2025, then soared by 103.7% to $14729.0 in 2026.
- The last three Exchange Rate Effect figures came in at $14729.0 (Q1 2026), -$397861.0 (Q4 2025), and -$37537.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.60 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -2.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -40.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 8.68 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | 14,729.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,729.00 |
| Mar 31, 2026 | 14,729.00 |
| Dec 31, 2025 | -397,861.00 |
| Dec 31, 2025 | -397,861.00 |
| Sep 30, 2025 | -37,537.00 |
| Sep 30, 2025 | -37,537.00 |
| Jun 30, 2025 | 179,401.00 |
| Jun 30, 2025 | 179,401.00 |
| Mar 31, 2025 | 42,500.00 |
| Mar 31, 2025 | 42,500.00 |
| Dec 31, 2024 | -288,748.00 |
| Dec 31, 2024 | -288,748.00 |
| Sep 30, 2024 | 47,537.00 |
| Sep 30, 2024 | 47,537.00 |
| Jun 30, 2024 | 28,283.00 |
| Jun 30, 2024 | 28,283.00 |
| Mar 31, 2024 | -28,270.00 |
| Mar 31, 2024 | -28,270.00 |